Clinical Trials Browser

Interventional × Breast Neoplasms × Everolimus × Clear all

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07340541 2026-04-13

EVOLVE-BDT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06428396 2026-03-24

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT05501769 2025-09-26

TACTIVE-E

Phase 1 Completed

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3 Recruiting

Breast Neoplasms

NCT03032406 2025-07-22

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Phase 2 Active not recruiting

53 enrolled 12 charts

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT00317720 2025-04-30

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Phase 1/2 Completed

40 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00253318 2025-04-27

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT03659136 2025-02-24

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Phase 2 Completed

103 enrolled 16 charts

Breast Neoplasms

NCT02531932 2025-02-19

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04818632 2024-12-17

AZD9833

Phase 1 Completed

Breast Neoplasms

NCT05293964 2024-11-29

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

Phase 2 Not yet recruiting

Breast Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

Phase 2 Recruiting

Breast Neoplasms

NCT03312738 2024-01-23

BOLERO-5

Phase 2 Completed

159 enrolled 25 charts

Breast Neoplasms

NCT05954442 2024-01-16

BCTOP-T-M03

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT00934895 2023-09-18

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Phase 1/2 Terminated

27 enrolled 12 charts

Breast Neoplasms

NCT01298713 2023-09-06

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Phase 2 Completed

Breast Neoplasms

NCT02028364 2023-08-24

PEARL

Phase 2 Completed

Breast Neoplasms

NCT00255788 2023-08-04

Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT01698918 2023-05-03

BOLERO-4

Phase 2 Completed

202 enrolled 19 charts

Breast Neoplasms

NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast Neoplasms

NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 6 charts

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT02236572 2022-02-01

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Phase 2 Terminated

17 enrolled 11 charts

Breast Neoplasms

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01931163 2021-07-20

NECTAR

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms